Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

A real-world comparative study found efgartigimod produced similar GBS disability score improvement to plasma exchange at 4 weeks, with significantly greater MRC sum score recovery at weeks 8 and 12, and a comparable safety profile.

Analysis of 1420 patients from the International GBS Outcome Study found no significant difference in GBS disability scores between IVIg and plasma exchange at 4 or 26 weeks after adjusting for key clinical covariates.

An exploratory analysis of the phase 3 ADHERE trial found serum NfL levels correlated with CIDP disease activity and declined with efgartigimod treatment in patients with elevated baseline levels.

The CAPTIVATE trial evaluates claseprubart, an active C1s inhibitor, across a broad CIDP population including SOC responders, refractory patients, and treatment-naive adults, with time to relapse as the primary endpoint in the double-blind phase.

Despite missing its primary end point, the SYNAPSE-CMT trial showed improvements in muscle strength and motor function with ignaseclant treatment in patients with Charcot-Marie-Tooth disease.

A phase 4 trial underway in the U.S. is examining whether patients with CIDP on stable IVIg can transition to efgartigimod PH20 SC within one week of their last infusion, without requiring documented disease worsening first.

Sanofi stops the phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy because of insufficient likelihood of efficacy, with no safety signals reported.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Jinsy A. Andrews, MD, Director of the ALS Clinic and Director of Clinical Trials at NYU Langone Health, discussed the evolving ALS treatment landscape, including emerging gene-targeted therapies, and the next generation of disease biomarkers.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

New exon‑51 skipping therapy boosts dystrophin and patient strength, with upcoming trial readouts aiming to support accelerated FDA approval.

Here's some of what is coming soon to NeurologyLive® this week.

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

Wearable accelerometer metric 6M95C tracks Duchenne progression beyond walking loss, delivering effort‑independent, real‑world outcomes to strengthen late‑stage clinical trials.

New phase 4 head-to-head data suggest Dysport may provide longer-lasting symptom control than Botox in adults with upper limb spasticity while maintaining comparable safety.

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

Experts debate how to sequence new gMG therapies, manage seronegative and special populations, and close biomarker and access gaps.

New RESTORE-FA results show DT-216P2 improved balance and fatigue within 4 weeks, with tolerable safety.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

Phase 3 AFFINITY DUCHENNE data showed that investigational RGX-202 achieved significant microdystrophin expression and correlated functional improvements in Duchenne muscular dystrophy, supporting plans for accelerated FDA approval.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.